Prevalence of Acute Renal Failure, Para-Clinical Outcomes, and Mortality in COVID-19 Patients.

IF 1.2 Q2 MEDICINE, GENERAL & INTERNAL
Nasrin Milani, Najmeh Majidi, Maryam Hami, Farzaneh Sharifipour, Zahra Ramatinejad, Fatemeh Rahmatinejad, Zahra Abbasi Shaye, Mona Kabiri
{"title":"Prevalence of Acute Renal Failure, Para-Clinical Outcomes, and Mortality in COVID-19 Patients.","authors":"Nasrin Milani, Najmeh Majidi, Maryam Hami, Farzaneh Sharifipour, Zahra Ramatinejad, Fatemeh Rahmatinejad, Zahra Abbasi Shaye, Mona Kabiri","doi":"10.3121/cmr.2024.1955","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives:</b> Although acute respiratory syndrome is the main manifestation of COVID-19 disease, one of the characteristics of the disease is acute kidney injury (AKI). This study aimed to assess the prevalence of kidney dysfunction and para-clinical outcomes in hospitalized COVID-19 patients and its relationship with mortality.<b>Methods:</b> This cross-sectional analytical study was carried out on 715 patients aged older than 16-years with a diagnosis of COVID-19 admitted to the tertiary teaching Imam Reza Hospital, Mashhad, Iran from February 2020 to February 2021. During hospitalization, these patients were evaluated for AKI based on the Kidney Disease Improving Global Outcomes classification and mortality. Demographic variables and laboratory data were extracted from the hospital information systems electronic database. The significant risk factors for the incidence of AKI were analyzed using SPSS software in the present study.<b>Results:</b> The mortality rate of the included patients was 18.9%, which expired during hospitalization. Mortality was higher among patients with stage 1-2 AKI (34.1%) and stage 3 AKI (44.9%) compared to patients without AKI (8.7%). Individuals in different stages of AKI were significantly older relative to the non-AKI patients; hence, aging could be considered as the predictor of AKI. Leukocytosis, lactate dehydrogenase (LDH), and blood urea nitrogen (BUN) were indicated as significant risk factors for the incidence of AKI.<b>Conclusions:</b> It was found that the prevalence of AKI was 37.2% in hospitalized COVID-19 patients, and there was an association between mortality and the incidence of AKI.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":"22 4","pages":"188-196"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849971/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine & Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3121/cmr.2024.1955","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Although acute respiratory syndrome is the main manifestation of COVID-19 disease, one of the characteristics of the disease is acute kidney injury (AKI). This study aimed to assess the prevalence of kidney dysfunction and para-clinical outcomes in hospitalized COVID-19 patients and its relationship with mortality.Methods: This cross-sectional analytical study was carried out on 715 patients aged older than 16-years with a diagnosis of COVID-19 admitted to the tertiary teaching Imam Reza Hospital, Mashhad, Iran from February 2020 to February 2021. During hospitalization, these patients were evaluated for AKI based on the Kidney Disease Improving Global Outcomes classification and mortality. Demographic variables and laboratory data were extracted from the hospital information systems electronic database. The significant risk factors for the incidence of AKI were analyzed using SPSS software in the present study.Results: The mortality rate of the included patients was 18.9%, which expired during hospitalization. Mortality was higher among patients with stage 1-2 AKI (34.1%) and stage 3 AKI (44.9%) compared to patients without AKI (8.7%). Individuals in different stages of AKI were significantly older relative to the non-AKI patients; hence, aging could be considered as the predictor of AKI. Leukocytosis, lactate dehydrogenase (LDH), and blood urea nitrogen (BUN) were indicated as significant risk factors for the incidence of AKI.Conclusions: It was found that the prevalence of AKI was 37.2% in hospitalized COVID-19 patients, and there was an association between mortality and the incidence of AKI.

COVID-19患者急性肾功能衰竭的患病率、准临床结局和死亡率
目的:急性呼吸综合征是COVID-19的主要表现,但其特征之一是急性肾损伤(AKI)。本研究旨在评估COVID-19住院患者肾功能不全的患病率和准临床结局及其与死亡率的关系。方法:对2020年2月至2021年2月在伊朗马什哈德伊玛目礼萨三级教学医院就诊的715例16岁以上诊断为COVID-19的患者进行横断面分析研究。在住院期间,根据肾脏疾病改善全球结局分类和死亡率对这些患者进行AKI评估。人口统计变量和实验室数据从医院信息系统电子数据库中提取。本研究采用SPSS软件对AKI发生的重要危险因素进行分析。结果:本组患者在住院期间死亡,死亡率为18.9%。与无AKI患者(8.7%)相比,1-2期AKI患者(34.1%)和3期AKI患者(44.9%)的死亡率更高。AKI不同阶段的个体相对于非AKI患者明显衰老;因此,年龄可以被认为是AKI的预测因子。白细胞增多、乳酸脱氢酶(LDH)和血尿素氮(BUN)是AKI发生的重要危险因素。结论:研究发现COVID-19住院患者AKI患病率为37.2%,死亡率与AKI发生率存在相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Medicine & Research
Clinical Medicine & Research MEDICINE, GENERAL & INTERNAL-
CiteScore
1.80
自引率
7.10%
发文量
25
期刊介绍: Clinical Medicine & Research is a peer reviewed publication of original scientific medical research that is relevant to a broad audience of medical researchers and healthcare professionals. Articles are published quarterly in the following topics: -Medicine -Clinical Research -Evidence-based Medicine -Preventive Medicine -Translational Medicine -Rural Health -Case Reports -Epidemiology -Basic science -History of Medicine -The Art of Medicine -Non-Clinical Aspects of Medicine & Science
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信